Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilzabrutinib versus placebo in active IgG4-related disease
NL-OMON61075Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in IgG4-related disease (IgG4-RD) comparing Rilzabrutinib with Placebo (2 arms). Primary endpoint: Time to first adjudicated clinical disease flare treated by the investigator during the blinded treatment period. Started Dec 2025; status: recruiting.
02
Drugs
rilzabrutinib
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NL-OMON61075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61075.